Q301--CYTOPATHOLOGY AND NEXT GENERATION SEQUENCING TESTING SERVICES

Solicitation 36C24226Q0875 is a Firm-Fixed-Price Indefinite Delivery Indefinite Quantity (IDIQ) contract issued by the Department of Veterans Affairs for the Northport VA Medical Center. The objective is to secure comprehensive, clinically validated molecular diagnostic testing using Next Generation Sequencing (NGS) to improve the management of thyroid nodules with indeterminate fine-needle aspiration (FNA) cytology. The contract covers a five-year performance period from October 1, 2026, to September 30, 2031, with a minimum quantity of 30 tests and a maximum of 600 tests. The scope includes cytopathology evaluation, reflex molecular testing, the provision of collection and shipping kits, and professional consultation. Award will be based on best-value, where technical capability and past performance are weighted more heavily than price. Key evaluation factors include diagnostic performance, molecular testing capabilities, quality management certifications such as CLIA and CAP, and the qualifications of key personnel, specifically board-certified molecular pathology oversight. While the solicitation is not set aside for small businesses, evaluation credit will be granted to Service-Disabled Veteran-Owned Small Businesses (SDVOSB) and Veteran-Owned Small Businesses (VOSB) verified in the VIP database. Quotes must be submitted electronically to Contract Specialist Mariangie Rivera by 5:00 PM EST on August 21, 2026.